Literature DB >> 14963154

Inhibition of human immunodeficiency virus type 1 replication by RNA interference directed against human transcription elongation factor P-TEFb (CDK9/CyclinT1).

Ya-Lin Chiu1, Hong Cao, Jean-Marc Jacque, Mario Stevenson, Tariq M Rana.   

Abstract

The human positive transcription elongation factor P-TEFb is composed of two subunits, cyclin T1 (hCycT1) and CDK9, and is involved in transcriptional regulation of cellular genes as well as human immunodeficiency virus type 1 (HIV-1) mRNA. Replication of HIV-1 requires the Tat protein, which activates elongation of RNA polymerase II at the HIV-1 promoter by interacting with hCycT1. To understand the cellular functions of P-TEFb and to test whether suppression of host proteins such as P-TEFb can modulate HIV infectivity without causing cellular toxicity or lethality, we used RNA interference (RNAi) to specifically knock down P-TEFb expression by degrading hCycT1 or CDK9 mRNA. RNAi-mediated gene silencing of P-TEFb in HeLa cells was not lethal and inhibited Tat transactivation and HIV-1 replication in host cells. We also found that CDK9 protein stability depended on hCycT1 protein levels, suggesting that the formation of P-TEFb CDK-cyclin complexes is required for CDK9 stability. Strikingly, P-TEFb knockdown cells showed normal P-TEFb kinase activity. Our studies suggest the existence of a dynamic equilibrium between active and inactive pools of P-TEFb in the cell and indicate that this equilibrium shifts towards the active kinase form to sustain cell viability when P-TEFb protein levels are reduced. The finding that a P-TEFb knockdown was not lethal and still showed normal P-TEFb kinase activity suggested that there is a critical threshold concentration of activated P-TEFb required for cell viability and HIV replication. These results provide new insights into the regulation of P-TEFb function and suggest the possibility that similar mechanisms for monitoring protein levels to modulate the activity of proteins may exist for the regulation of a variety of other enzymatic pathways.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14963154      PMCID: PMC369228          DOI: 10.1128/jvi.78.5.2517-2529.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  62 in total

Review 1.  P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II.

Authors:  D H Price
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

2.  Positive transcription elongation factor B phosphorylates hSPT5 and RNA polymerase II carboxyl-terminal domain independently of cyclin-dependent kinase-activating kinase.

Authors:  J B Kim; P A Sharp
Journal:  J Biol Chem       Date:  2001-01-05       Impact factor: 5.157

3.  Different phosphorylated forms of RNA polymerase II and associated mRNA processing factors during transcription.

Authors:  P Komarnitsky; E J Cho; S Buratowski
Journal:  Genes Dev       Date:  2000-10-01       Impact factor: 11.361

4.  Dynamic association of capping enzymes with transcribing RNA polymerase II.

Authors:  S C Schroeder; B Schwer; S Shuman; D Bentley
Journal:  Genes Dev       Date:  2000-10-01       Impact factor: 11.361

5.  The 7SK small nuclear RNA inhibits the CDK9/cyclin T1 kinase to control transcription.

Authors:  Z Yang; Q Zhu; K Luo; Q Zhou
Journal:  Nature       Date:  2001-11-15       Impact factor: 49.962

6.  Flavopiridol inhibits P-TEFb and blocks HIV-1 replication.

Authors:  S H Chao; K Fujinaga; J E Marion; R Taube; E A Sausville; A M Senderowicz; B M Peterlin; D H Price
Journal:  J Biol Chem       Date:  2000-09-15       Impact factor: 5.157

7.  A highly purified RNA polymerase II elongation control system.

Authors:  D B Renner; Y Yamaguchi; T Wada; H Handa; D H Price
Journal:  J Biol Chem       Date:  2001-09-11       Impact factor: 5.157

8.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells.

Authors:  S M Elbashir; J Harborth; W Lendeckel; A Yalcin; K Weber; T Tuschl
Journal:  Nature       Date:  2001-05-24       Impact factor: 49.962

9.  DSIF and NELF interact with RNA polymerase II elongation complex and HIV-1 Tat stimulates P-TEFb-mediated phosphorylation of RNA polymerase II and DSIF during transcription elongation.

Authors:  Y H Ping; T M Rana
Journal:  J Biol Chem       Date:  2000-12-08       Impact factor: 5.157

10.  Cyclin T1 domains involved in complex formation with Tat and TAR RNA are critical for tat-activation.

Authors:  D Ivanov; Y T Kwak; E Nee; J Guo; L F García-Martínez; R B Gaynor
Journal:  J Mol Biol       Date:  1999-04-23       Impact factor: 5.469

View more
  49 in total

1.  P-TEFb kinase complex phosphorylates histone H1 to regulate expression of cellular and HIV-1 genes.

Authors:  Siobhan K O'Brien; Hong Cao; Robin Nathans; Akbar Ali; Tariq M Rana
Journal:  J Biol Chem       Date:  2010-06-15       Impact factor: 5.157

Review 2.  RNA interference and antiviral therapy.

Authors:  Yan Ma; Chu-Yan Chan; Ming-Liang He
Journal:  World J Gastroenterol       Date:  2007-10-21       Impact factor: 5.742

Review 3.  High-throughput RNA interference screens integrative analysis: Towards a comprehensive understanding of the virus-host interplay.

Authors:  Sandeep Amberkar; Narsis A Kiani; Ralf Bartenschlager; Gualtiero Alvisi; Lars Kaderali
Journal:  World J Virol       Date:  2013-05-12

4.  P-TEFb is not an essential elongation factor for the intronless human U2 snRNA and histone H2b genes.

Authors:  Joanne Medlin; Andrew Scurry; Alice Taylor; Fan Zhang; B Matija Peterlin; Shona Murphy
Journal:  EMBO J       Date:  2005-11-24       Impact factor: 11.598

5.  Nuclear factor 45 (NF45) is a regulatory subunit of complexes with NF90/110 involved in mitotic control.

Authors:  Deyu Guan; Nihal Altan-Bonnet; Andrew M Parrott; Cindy J Arrigo; Quan Li; Mohammed Khaleduzzaman; Hong Li; Chee-Gun Lee; Tsafi Pe'ery; Michael B Mathews
Journal:  Mol Cell Biol       Date:  2008-05-05       Impact factor: 4.272

Review 6.  RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA?

Authors:  Sandesh Subramanya; Sang-Soo Kim; N Manjunath; Premlata Shankar
Journal:  Expert Opin Biol Ther       Date:  2010-02       Impact factor: 4.388

7.  Identification of flavopiridol analogues that selectively inhibit positive transcription elongation factor (P-TEFb) and block HIV-1 replication.

Authors:  Akbar Ali; Animesh Ghosh; Robin S Nathans; Natalia Sharova; Siobhan O'Brien; Hong Cao; Mario Stevenson; Tariq M Rana
Journal:  Chembiochem       Date:  2009-08-17       Impact factor: 3.164

8.  Selective control of gene expression by CDK9 in human cells.

Authors:  Judit Garriga; Hongbo Xie; Zoran Obradovic; Xavier Graña
Journal:  J Cell Physiol       Date:  2010-01       Impact factor: 6.384

9.  Controlling cellular P-TEFb activity by the HIV-1 transcriptional transactivator Tat.

Authors:  Lisa Muniz; Sylvain Egloff; Bettina Ughy; Beáta E Jády; Tamás Kiss
Journal:  PLoS Pathog       Date:  2010-10-14       Impact factor: 6.823

10.  P-TEFb- the final frontier.

Authors:  Jiri Kohoutek
Journal:  Cell Div       Date:  2009-09-02       Impact factor: 5.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.